Company Profiles

driven by the PitchBook Platform

Oxagen

Description

Developer of small molecule drugs designed to treat inflammatory and respiratory diseases. The company's small molecule drugs comprise of an oral anti-inflammatory agent, CRTH2 antagonist, an oral molecule for asthma and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis, enabling patients to receive enhanced results from the medicines.

1996

Founded

PRIVATE

Status

51-200

Employees

2ndary - Private

Latest Deal Type

$169M

Total Amount Raised

13

Investors

Description

Developer of small molecule drugs designed to treat inflammatory and respiratory diseases. The company's small molecule drugs comprise of an oral anti-inflammatory agent, CRTH2 antagonist, an oral molecule for asthma and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis, enabling patients to receive enhanced results from the medicines.

Website:

www.oxagen.co.uk

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Delivery

Other Industries

Pharmaceuticals

Primary Office

Innovation Centre 99 Park Drive Milton Park, Oxon Abingdon OX14 4RYEngland +44 (0)12 3584 1561
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Oxagen's full profile, request a free trial.

Oxagen Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Oxagen Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Oxagen Investors (13)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
3i GroupPE/BuyoutMinority000 0000000 0000
Aberdeen SVG Private EquityPE/BuyoutMinority000 0000000 0000
Advent Venture PartnersVenture CapitalMinority000 0000000 0000
Bessemer Venture PartnersVenture CapitalMinority000 0000000 0000
International Biotechnology TrustOtherMinority000 0000000 0000
3i Group PE/Buyout
Aberdeen SVG Private Equity PE/Buyout
Advent Venture Partners Venture Capital
Bessemer Venture Partners Venture Capital
International Biotechnology Trust Other

Oxagen Executive Team (1)

NameTitleBoard
Seat
Contact
Info
John Bell Ph.DCo-Founder & Board Member
John Bell Ph.D Co-Founder & Board Member

Oxagen Board Members (7)

NameRepresentingRoleSinceContact
Info
Alan Ezekowitz Ph.DSelfBoard Member000 0000
Anja König Ph.DNovartis Venture FundManaging Director000 0000
Erich SchlickWellington PartnersGeneral Partner000 0000
John Bell Ph.DSelfCo-Founder & Board Member000 0000
Luke Evnin Ph.DMPM CapitalCo-Founder & Managing Director000 0000
Alan Ezekowitz Ph.D Board Member Self
Anja König Ph.D Managing Director Novartis Venture Fund
Erich Schlick General Partner Wellington Partners
John Bell Ph.D Co-Founder & Board Member Self
Luke Evnin Ph.D Co-Founder & Managing Director MPM Capital
Request full access to PitchBook